Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Gregory Bull / AP
The cost to develop a cancer drug may be significantly lower than what some companies claim, according to a new study published in JAMA Internal Medicine.
- The study found the median cost to develop a cancer drug is $648 million — much lower than the commonly cited $2 billion figure, which originated from a Tufts Center for the Study of Drug Development report that used private datasets.
- Drug companies justify high prices for new drugs by citing high research and development costs. But in this study of 10 cancer drugs developed by biotech companies and approved between 2006 and 2015, some of the companies made more than 10 times as much as they spent on research and development.
- Limitations: Business Insider points out that the study didn't look at larger pharmaceutical companies, which may invest differently in R&D, and exclusively analyzed cancer drugs that may carry different costs — and revenues — compared to other fields.
Go deeper: Putting a price on new cancer treatments